{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:57:38Z","timestamp":1781690258667,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EUNextGenerationEU","award":["09I03-03-V03-00046"],"award-info":[{"award-number":["09I03-03-V03-00046"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Most bladder cancer cases present as non-muscle-invasive bladder cancer (NMIBC), with the course of multiple recurrences leading to stage progression to muscle-invasive bladder cancer (MIBC) in 10\u201320% of cases, which is associated with higher morbidity and mortality. Accurate histopathologic classification of bladder cancer remains important for patient management. Methods: This retrospective\u2013prospective observational cohort study was conducted on 244 transurethral resection specimens. Immunohistochemistry assessed CK5\/6, CK20, and apoptosis-inducing factor (AIF) using three representations: intensity, percentage of positive cells, and multiplicative score. Discrimination between NMIBC (pTa\/pT1) and MIBC (\u2265pT2), and between low-grade (LG) and high-grade (HG) tumors, was evaluated using ROC\/AUC analysis and logistic regression. The main analysis focused on cross-sectional marker performance in primary\/non-recurrent tumors. Recurrent tumors were analyzed only as an exploratory subgroup. Tumors were also categorized into basal, luminal, mixed\/double-positive, and double-negative phenotypes using thresholds of 10% for CK5\/6 and CK20. Results: For stage discrimination, all three markers showed modest separation. The best-performing representation was CK5\/6 intensity (AUC 0.641; lower in MIBC). For grade discrimination, the AIF score showed the highest performance (AUC 0.729, higher in HG). Combining markers improved model performance (NMIBC vs. MIBC: AUC 0.784; strict LG vs. HG: AUC 0.778). Using the 10% cutoff in non-recurrent tumors, mixed\/double-positive tumors had the lowest MIBC proportion (6.0%) and double-negative tumors the highest (46.7%). Conclusions: CK5\/6, CK20, and AIF provide modest discrimination between stages, with lower CK5\/6 and CK20, and higher AIF, in MIBC. The AIF score shows the highest separation between grades and may serve as a useful non-proliferation marker for grading, particularly when interpreted alongside CK5\/6 and CK20 in a simple immunohistochemical panel.<\/jats:p>","DOI":"10.3390\/jcm15124693","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:22:56Z","timestamp":1781684576000},"page":"4693","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AIF, CK5\/6, and CK20 in Bladder Urothelial Carcinoma: A Cross-Sectional Immunohistochemical Study of Grade and Stage Associations"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8170-1850","authenticated-orcid":false,"given":"Pavel","family":"Babal","sequence":"first","affiliation":[{"name":"Institute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-4898","authenticated-orcid":false,"given":"Stefan","family":"Harsanyi","sequence":"additional","affiliation":[{"name":"Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kern","sequence":"additional","affiliation":[{"name":"Institute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-3981","authenticated-orcid":false,"given":"Kristina Mikus","family":"Kuracinova","sequence":"additional","affiliation":[{"name":"Institute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4053-7326","authenticated-orcid":false,"given":"Lucia","family":"Krivosikova","sequence":"additional","affiliation":[{"name":"Institute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislav","family":"Trebaticky","sequence":"additional","affiliation":[{"name":"Department of Urology, Academician Ladislav D\u00e9rer Hospital, University Hospital Bratislava, 833 05 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Ziaran","sequence":"additional","affiliation":[{"name":"Department of Urology, Ru\u017einov Hospital, Faculty of Medicine, Comenius University and University Hospital Bratislava, 826 06 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Janegova","sequence":"additional","affiliation":[{"name":"Institute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-7286","authenticated-orcid":false,"given":"Pavol","family":"Janega","sequence":"additional","affiliation":[{"name":"Institute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia"},{"name":"Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, 813 71 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2025.12.011","article-title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","volume":"89","author":"Filho","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Barber, N., and Ali, A. (2022). The Etiology of Bladder Cancer. Urologic Cancers, Exon Publications.","DOI":"10.36255\/exon-publications-urologic-cancers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The Global Burden of Urinary Bladder Cancer: An Update","volume":"38","author":"Richters","year":"2020","journal-title":"World J. Urol."},{"key":"ref_4","unstructured":"(2026, February 09). BlueBooksOnline. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/36."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sanguedolce, F., Zanelli, M., Palicelli, A., Ascani, S., Zizzo, M., Cocco, G., Bj\u00f6rnebo, L., Lantz, A., Falagario, U.G., and Cormio, L. (2022). Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147819"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e21200019","DOI":"10.14440\/bladder.2024.0031","article-title":"Molecular Classification Using Lund University Algorithm and Clinical Correlations in Muscle-Invasive Bladder Cancer: Insights from a Retrospective Study","volume":"11","author":"Campobasso","year":"2024","journal-title":"Bladder"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular Pathology of Urothelial Carcinoma","volume":"113","author":"Cimadamore","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4920236","DOI":"10.1155\/2020\/4920236","article-title":"CK20 and CK5\/6 Immunohistochemical Staining of Urothelial Neoplasms: A Perspective","volume":"2020","author":"Akhtar","year":"2020","journal-title":"Adv. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sikic, D., Keck, B., Wach, S., Taubert, H., Wullich, B., Goebell, P.J., Kahlmeyer, A., Olbert, P., Isfort, P., and Nimphius, W. (2017). Immunohistochemiocal Subtyping Using CK20 and CK5 Can Identify Urothelial Carcinomas of the Upper Urinary Tract with a Poor Prognosis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179602"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yoo, D., Min, K.-W., Pyo, J.-S., and Kim, N.Y. (2023). Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and P53 in Urothelial Carcinoma In Situ. Medicina, 59.","DOI":"10.20944\/preprints202308.0323.v1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.anndiagpath.2013.10.006","article-title":"The Role of Immunohistochemistry in the Diagnosis of Flat Urothelial Lesions: A Study Using CK20, CK5\/6, P53, Cd138, and Her2\/Neu","volume":"18","author":"Jung","year":"2014","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kraevska, E., and Popovska, S. (2025). Immunohistochemistry-Based Molecular Profiling of Muscle-Invasive Bladder Cancer: Analysis of 100 Consecutive Cases with Morphological Correlation. Med. Sci., 13.","DOI":"10.3390\/medsci13030202"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Harsanyi, S., Novakova, Z.V., Neuschlova, L., Galbavy, S., Danisovic, L., Ziaran, S., and Bevizova, K. (2026). Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer. J. Clin. Med., 15.","DOI":"10.3390\/jcm15010338"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kvikstad, V., Lillesand, M., Gudlaugsson, E., Mangrud, O.M., Rewcastle, E., Skaland, I., Baak, J.P.A., and Janssen, E.A.M. (2024). Proliferation and Immunohistochemistry for P53, CD25 and CK20 in Predicting Prognosis of Non-Muscle Invasive Papillary Urothelial Carcinomas. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0297141"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4149\/neo_2017_213","article-title":"Prognostic Value of Apoptosis Inducing Factor in Uveal Melanoma","volume":"64","author":"Krasnik","year":"2017","journal-title":"Neoplasma"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Letkovska, K., Babal, P., Cierna, Z., Schmidtova, S., Liskova, V., Kalavska, K., Miskovska, V., Horak, S., Rejlekova, K., and Chovanec, M. (2021). Prognostic Value of Apoptosis-Inducing Factor (AIF) in Germ Cell Tumors. Cancers, 13.","DOI":"10.3390\/cancers13040776"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104860","DOI":"10.1016\/j.yexmp.2023.104860","article-title":"Cytokeratin 20 Expression Is Linked to Stage Progression and to Poor Prognosis in Advanced (pT4) Urothelial Carcinoma of the Bladder","volume":"131","author":"Bruch","year":"2023","journal-title":"Exp. Mol. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wang, C.-C., Tsai, Y.-C., and Jeng, Y.-M. (2019). Biological Significance of GATA3, Cytokeratin 20, Cytokeratin 5\/6 and P53 Expression in Muscle-Invasive Bladder Cancer. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221785"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic Subtypes of High-Grade Bladder Cancer Reflect the Hallmarks of Breast Cancer Biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bju.16828","article-title":"Enhanced Prognostic Value of Four-Tier Hybrid Grading System in Ta Non-Muscle-Invasive Bladder Cancer","volume":"136","author":"Ferro","year":"2025","journal-title":"BJU Int."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Goutas, D., Palamaris, K., Stofas, A., Politakis, N., Despotidi, A., Giannopoulou, I., Goutas, N., Vlachodimitropoulos, D., Kavantzas, N., and Lazaris, A.C. (2023). Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression. Cancers, 15.","DOI":"10.3390\/cancers15010188"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21037\/tau-22-538","article-title":"Identification and Validation of Immunohistochemical Marker Panels to Predict the Prognosis of Muscle Invasive Bladder Cancer","volume":"12","author":"Ying","year":"2023","journal-title":"Transl. Androl. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Do, A.T., Pham, Q.T., Nguyen, N.M.T., Nguyen, P.N., Bui, T.T.T., and Ngo, Q.D. (2024). Immunohistochemical Evaluation of Basal and Luminal Markers in Bladder Cancer: A Study from a Single Institution. Life, 14.","DOI":"10.3390\/life14121670"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAI.0000000000001272","article-title":"Deciphering the Molecular Landscape of Urothelial Carcinoma: Immunohistochemistry-Based Subtyping Using 4 Easily Available Antibodies for Cost-Effective Stratification","volume":"33","author":"Indulkar","year":"2025","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2023.41.6_suppl.557","article-title":"Immunohistochemical (IHC) Subtypes of Metastatic Bladder Cancer (mBC) Using GATA3 and CK5\/6","volume":"41","author":"Nelson","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4103\/ijpm.ijpm_290_25","article-title":"Basal Subtype of Invasive Urothelial Carcinoma of the Bladder Has Aggressive Behavior and Poor Prognosis: An Immunohistochemistry-Based Study","volume":"68","author":"Venkatakrishnan","year":"2025","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41422-019-0181-4","article-title":"AIF-Regulated Oxidative Phosphorylation Supports Lung Cancer Development","volume":"29","author":"Rao","year":"2019","journal-title":"Cell Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14707","DOI":"10.1074\/jbc.RA118.004022","article-title":"AIF Promotes a JNK1-Mediated Cadherin Switch Independently of Respiratory Chain Stabilization","volume":"293","author":"Scott","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bognar, Z., Fekete, K., Antus, C., Hocsak, E., Bognar, R., Tapodi, A., Boronkai, A., Farkas, N., Gallyas, F., and Sumegi, B. (2017). Desethylamiodarone\u2014A Metabolite of Amiodarone\u2014Induces Apoptosis on T24 Human Bladder Cancer Cells via Multiple Pathways. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189470"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4693\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:27:09Z","timestamp":1781688429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124693"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124693","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}